Analyst Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Esperion and keeping the price target at $16.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Joseph Pantginis has given his Buy rating due to a combination of factors including the promising clinical data from the CLEAR Outcomes Trial and the ongoing commercial success of Esperion’s product. The trial results have shown significant reductions in LDL-C and major adverse cardiovascular events (MACE) among statin-intolerant patients, which highlights the potential of bempedoic acid as an effective treatment option.
Moreover, the continued commercial uptake, evidenced by the U.S. product revenue of $87.3 million, indicates a strong market presence and growing acceptance among healthcare providers. These factors, coupled with the attention the trial has garnered from physicians, underscore the potential for further growth and expansion in the treatment of high-risk cardiovascular patients.
Pantginis covers the Healthcare sector, focusing on stocks such as Lexicon Pharmaceuticals, Esperion, and Travere Therapeutics. According to TipRanks, Pantginis has an average return of 2.2% and a 44.09% success rate on recommended stocks.
In another report released on November 6, Needham also maintained a Buy rating on the stock with a $4.00 price target.